Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares

Rhea-AI Filing Summary

Rallybio Corp director Helen M. Boudreau exercised options to acquire 3,562 shares of Common Stock on July 6, 2026 at an exercise price of $2.38 per share. Following the transaction, she directly holds 6,542 shares of Common Stock. The options exercised were originally rights to buy Rallybio common stock.

Insights

Equity compensation analyst

Director completed a routine option exercise and increased direct share ownership.

Director Helen M. Boudreau exercised options covering 3,562 shares of Rallybio Corp Common Stock at an exercise price of $2.38 per share on 2026-07-06. This is coded as an exercise or conversion of a derivative security, not an open-market purchase.

After this exercise, Boudreau directly holds 6,542 common shares. The underlying option, labeled "Option (Right to Buy)", had an exercise price of $2.38 and an expiration date of 2035-05-13. No open-market sales or tax-withholding dispositions are reported in this filing, and the transactionSummary shows one option exercise and a neutral net buy/sell direction.

Insider Trade Summary

Net Buyer: 3,562 shares

Net Buy 2 txns

Insider Boudreau Helen M

Role Director

Type	Security	Shares	Price	Value
Exercise	Option (Right to Buy)	3,562	$0.00	$0.00
Exercise	Common Stock	3,562	$2.38	$8K

Holdings After Transaction: Option (Right to Buy) — 0 shares (Direct); Common Stock — 6,542 shares (Direct)

Key Figures

Shares acquired via option exercise: 3,562 shares Exercise price per share: $2.38 per share Shares held after transaction: 6,542 shares +3 more

6 metrics

Shares acquired via option exercise 3,562 shares Common Stock acquired on July 6, 2026 through exercise of derivative security

Exercise price per share $2.38 per share Exercise or conversion price of the Option (Right to Buy) for Rallybio Common Stock

Shares held after transaction 6,542 shares Total Rallybio Common Stock directly owned by Helen M. Boudreau following the transaction

Option expiration date May 13, 2035 Expiration date of the Option (Right to Buy) that was exercised

Option exercise date May 13, 2026 Exercise date associated with the derivative security in the Form 4 data

Derivative exercise count 1 exercise, 3,562 shares transactionSummary shows one option exercise covering 3,562 shares

Key Terms

Option (Right to Buy), derivative security, transaction code, direct or indirect ownership

4 terms

Option (Right to Buy) financial

"The security title is listed as "Option (Right to Buy)" for the derivative transaction."

derivative security financial

"The transaction code description states "Exercise or conversion of derivative security" for this filing."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

transaction code financial

"The filing uses transaction code "M" to indicate an exercise or conversion of derivative security."

direct or indirect ownership financial

"The field "direct_or_indirect" is marked "D" indicating direct or indirect ownership type."

FAQ

What did Rallybio (RLYB) director Helen Boudreau report in this Form 4?

Helen M. Boudreau reported exercising options for 3,562 shares of Rallybio Corp Common Stock at $2.38 per share on July 6, 2026, increasing her direct holdings to 6,542 shares.

Did Rallybio (RLYB) director Helen Boudreau buy or sell shares on the market?

She did not report any open-market buys or sells. The Form 4 shows only an option exercise (exercise or conversion of a derivative security) for 3,562 shares at an exercise price of $2.38 per share.

How many Rallybio (RLYB) shares does Helen Boudreau own after this transaction?

After the reported transaction, Helen M. Boudreau directly owns 6,542 shares of Rallybio Corp Common Stock, as stated in the post-transaction holdings field on the Form 4.

What were the key terms of the option Helen Boudreau exercised at Rallybio (RLYB)?

The exercised instrument was an "Option (Right to Buy)" for 3,562 underlying common shares, with an exercise price of $2.38 and an expiration date of May 13, 2035.

How many options did Rallybio (RLYB) director Helen Boudreau exercise in this filing?

She exercised options relating to 3,562 shares of underlying Rallybio common stock. After the exercise, the Form 4 shows zero derivative shares remaining for that specific option position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 04:15 PM Accepted by SEC EDGAR 07/10/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudreau Helen M

(Last) (First) (Middle)

C/O RALLYBIO CORPORATION

PO BOX 325

(Street)

EAST BERLIN CONNECTICUT 06023

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rallybio Corp [ RLYB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		M		3,562	A	$2.38	6,542	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)	$2.38	07/06/2026		M			3,562	05/13/2026	05/13/2035	Common Stock	3,562	$0.00	0	D

Explanation of Responses:

	By: /s/ Jonathan Lieber, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)